메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

존슨앤드존슨, APHRS 및 JPHRS에서 다양한 임상시험과 실사용 시험을 통해 거둔 펄스장 절제술의 최근 성과 공개

시술 부위 세척 과정을 최적화하고 일관된 시술 결과를 기대할 수 있는 새로운 안전성, 유효성 및 시술 절차 개선 데이터를 중점적으로 다루는 구두 발표 시간도 마련 요코하마, 2025년 11월 4일 -- 심장 부정맥 치료 분야의 세계적인 선두 기업1인 존슨앤드존슨 메드테크(Johnson & Johnson MedTech)가 오늘 심방세동(AF) 치료 목적의 펄스장 절제술(PFA)에 완전 통합형 베리펄스(VARIPULSE™) 플랫폼을 이용해 확보한 새로운 임상 및 실사용 데이터를 아시아ㆍ태평양 부정맥학회(Asia Pacific Heart Rhythm Society, APHRS) 및 일본 부정맥학회(Japanese Heart Rhythm Society, JHRS)의 공동 연례 회의에서 공개할 예정이라고 발표했다. 이 연례 회의는 2025년 11월 12일~15일 일본 요코하마에서 개최된다. 이 완전 통합형 플랫폼은 베리펄스 카테터(VARIPULSE™ Catheter), 트루펄스 제너레이터(TRUPULSE™ Generator), 그리고 카토 3 매핑 시스템 베리펄스 소프트웨어(CARTO™ 3 Mapping System V
- 김갑성 기자
- 2025-11-04 03:56
CQ Medical® Appoints Michael Galbus as Chief Executive Officer, Mike Sutter as Chairman of the Board of Directors

AVONDALE, Pa., Nov. 4, 2025 -- CQ Medical is pleased to announce the appointment of Michael Galbus as Chief Executive Officer. Michael previously served as Chief Operating Officer, where he played a key role in enhancing operational performance, advancing the company's growth strategy, and building trust across the executive team while championing the growth and development of his team members. A cancer survivor, Michael has a deeply personal connection to CQ Medical's mission of improving care and outcomes for patients and clinicians. He is recognized for his collaborative lea
- 김갑성 기자
- 2025-11-04 02:00
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

SHANGHAI, Nov. 3, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ platform for relapsed/refractory multiple myeloma (R/R MM), and for CT1190B, an allogeneic CD19/CD20-targeting CAR-T product candidate for relapsed/refractory non-Hodgkin's lymphoma (R/R NHL). The data showed that both allogeneic CAR-T products demonstrated initially favorable safety profiles and encouragi
- 김갑성 기자
- 2025-11-03 22:15
EmeTerm Wristband Significantly Reduces Postoperative Nausea and Vomiting in Major Orthopedic Surgeries

VANCOUVER, BC, Nov. 3, 2025 -- WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial in The Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits of the EmeTerm wristband in reducing postoperative nausea and vomiting (PONV) in patients undergoing total hip or knee arthroplasty (THA/TKA) under spinal anesthesia. The study aimed to evaluate whether the addition of the EmeTerm wristband to conventional antiemetic therapy could enhance prevention of PONV after orthopedic surgeries. This randomized controlled study
- 김갑성 기자
- 2025-11-03 22:00
Sanyou Bio and Shanghai ZJ Bio-Tech Sign Strategic Cooperation Agreement on Automated Development of Innovative Biologics to Jointly Tackle R&D Bottlenecks and Provide New Momentum for Innovative Drug R&D

SHANGHAI, Nov. 3, 2025 -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a strategic cooperation agreement on the automated development of innovative biologics. This collaboration aims to jointly tackle drug development bottlenecks by introducing automation technology to significantly shorten the R&D cycle for innovative drugs. According to the agreement, Sanyou Bio will upgrade the
- 김갑성 기자
- 2025-11-03 22:00
Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO

Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 -- Samsung Biologics (KRX: 207940.KS) today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and business specialization as a leading pure-play Contract Development and Manufacturing Organization (CDMO). Following approval by its Board of Directors, Samsung Biologics separated its investment an
- 김갑성 기자
- 2025-11-03 20:00
TCT 2025 | Robot-Assisted PCI Enters a New Era: Results of the PANVIS STAR Multicenter Randomized Controlled Trial

SHANGHAI, Nov. 3, 2025 -- The 37th Annual Transcatheter Cardiovascular Therapeutics (TCT2025) symposium was held grandly in San Francisco, USA, attracting widespread attention from the global cardiovascular community. On the morning of October 28th (local time), during the "Innovation Session: Robotics and AI-Enhanced Interventions," Dr. Wang Rui, representing the team of Academician Ge Junbo from Zhongshan Hospital Affiliated to Fudan University, presented to the world for the first time the safety and efficacy data from the multicenter randomized controlled trial of China's indepe
- 김갑성 기자
- 2025-11-03 18:04
Anthill Cloud: Transforming Pharma Marketing with AI, Modular Content, and Omnichannel Engagement

COPENHAGEN, Denmark, Nov. 3, 2025 -- Anthill , a leading content excellence and technology partner to the life sciences industry, has announced the launch of Anthill Cloud™ — an innovative platform that combines AI, modular content, and personalized engagement in one connected cloud ecosystem. Designed specifically for Pharma, MedTech, and Biotech, Anthill Cloud unifies content creation, governance, and omnichannel activation, accelerates time-to-market, and elevates HCP engagement. Anthill Cloud brings together three powerful modules: Arcane™ – A
- 김갑성 기자
- 2025-11-03 17:00
Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management

Wegovy® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in the presence of at least one related health condition. In Hong Kong, with over 30% of adults classified as obese[1] and 20% of adolescents being overweight or obese[2], Wegovy® offers an effective treatment option to help combat the rising health burden. The launch of Wegovy® in Hong Kong extends Novo Nordisk's commitment to addressin
- 김갑성 기자
- 2025-11-03 16:48
Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS

Key oral presentations highlight new safety, efficacy and workflow improvements data to optimize irrigation and support consistent procedural outcomes. YOKOHAMA, Japan, Nov. 3, 2025 -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment1, today announced that new clinical and real-world data from its integrated-by-design VARIPULSE™ Platform in pulsed field ablation (PFA) procedures for atrial fibrillation (AF) will be presented at the Asia Pacific Heart Rhythm Society (APHRS) and the Japanese Heart Rhythm Society (JHRS) joint annual meeting, 12–15 Nov
- 김갑성 기자
- 2025-11-03 14:35

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 07시 40분